"Pharma and biotech are moving aggressively across the digital divide to improve the quality of research data and increase the value they receive for investment in clinical trials," said MedAvante president and co-founder Amy Ellis. "Ian Neilson has been at the forefront of this paradigm since it began and we welcome his leadership in helping MedAvante's clients move to the next level."
At Covance, Neilson was a member of the Clinical Development executive leadership team, developing the IT roadmap for long range strategic plans, and he oversaw a team of 100 IT professionals responsible for successfully delivering a multi-year, multi-million dollar process and technology transformation program. Neilson previously led IT Architecture and Compliance for Covance with responsibility for establishing and implementing IT standards, security, and quality and compliance processes across the company.
"MedAvante has expanded rapidly into new areas of clinical trial management, especially with regard to collecting, managing and understanding essential clinical data," said Ellis. "Ian brings us the expertise, scope of knowledge and practical experience we need not only to ensure our processes operate flawlessly and continue to protect every data point, but also to find new ways for our customers to obtain greater and greater value from the data we provide."
MedAvante is the global clinical data services company dedicated to maximizing signal detection in clinical trials. Founded in 2002, MedAvante pioneered Central Ratings, a groundbreaking clinical trial methodology. This heritage of clinical expertise, coupled with technical innovation and operational skills, enabled MedAvante to develop the electronic source (eSource) platform, Virgil, the first such technology to replace costly and error-prone paper rating scales with real-time digital collection and cloud management of source data. Designed by clinicians for clinicians, Virgil offers built-in clinical guidance to ensure accurate, standardized assessments. MedAvante helps brings better drug therapies to market through smarter, faster clinical trials. Based in Hamilton, NJ with operations teams in the US, Germany, Russia and Japan, MedAvante delivers services for clinical trials in more than 40 countries worldwide. For more information, please visit www.medavante.com.
To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/ian-neilson-joins-medavante-as-global-it-leader-300404252.html
SOURCE MedAvante, Inc.